Monopar Reports Q3 2026 Net Loss of $6.2 Million

Monopar Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $0.72 per share, compared with a $3.4 million loss, or $0.48 per share, in the prior-year quarter. Cash, cash equivalents and investments totaled $129.4 million at September 30, 2026, and the company expects its funds t…